Mark S. Kleven
Chief Operating Officer at Neurolixis, Inc.
Profile
Mark S.
Kleven is currently the Operations Director at Neurolixis, Inc. He previously worked as the Vice President-PreClinical Development at Ceptaris Therapeutics, Inc., Head-Behavioral Pharmacology at Physicians Formula Holdings, Inc., and Principal at The University of Chicago.
He earned a doctorate degree from the University of Minnesota in 1986.
Mark S. Kleven active positions
| Companies | Position | Start |
|---|---|---|
Neurolixis, Inc.
 Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Chief Operating Officer | - |
Former positions of Mark S. Kleven
| Companies | Position | End |
|---|---|---|
Physicians Formula Holdings, Inc.
 Physicians Formula Holdings, Inc. Specialty StoresRetail Trade Physicians Formula Holdings, Inc. engages in the development, marketing, and sale of cosmetic and skin care products. The company was founded in 1937 and is headquartered in Azusa, CA. | Corporate Officer/Principal | - |
| The University of Chicago | Corporate Officer/Principal | - |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
Training of Mark S. Kleven
| University of Minnesota | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Physicians Formula Holdings, Inc.
Physicians Formula Holdings, Inc. Specialty StoresRetail Trade Physicians Formula Holdings, Inc. engages in the development, marketing, and sale of cosmetic and skin care products. The company was founded in 1937 and is headquartered in Azusa, CA. | Retail Trade |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Mark S. Kleven